<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13372">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035007</url>
  </required_header>
  <id_info>
    <org_study_id>Version 2, 17.04.09 / EK1649</org_study_id>
    <nct_id>NCT02035007</nct_id>
  </id_info>
  <brief_title>Transpulmonary Thermodilution Measurements in Patients With Heart Diseases</brief_title>
  <official_title>Transpulmonary Thermodilution Measurements in Patients With Heart Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the validation of the PiCCO (Pulse Contour Cardiac
      Output)-derived transpulmonary thermodilution technology in patients with heart diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  How do PiCCO and PAC (pulmonary artery catheter) derived hemodynamic variables change
           in different cardiac pathologies?

        -  How do PiCCO hemodynamic variables compare to transthoracic echocardiographic
           parameters in different cardiac pathologies?

        -  How does GEDV (global enddiastolic volume) correlate with left ventricles end-diastolic
           volume (LVEDV) assessed by LV (left ventricle) ventriculography and echocardiography?

        -  How do PiCCO cardiac function variables (GEF [global ejection fraction]; CFI [cardiac
           function index]) correlate with LV dP/dt max, LVEF (left ventricular ejection fraction)
           assessed by LV ventriculography and echocardiography, LVFAC (left ventricular
           fractional area of change), LV stroke work index (LVSWI) and cardiac power (CP)?

        -  How does GEDV compare to LVEDV and left ventricular end-diastolic pressure (LVEDP) as
           assessed by the pulmonary artery occlusion pressure (PAOP)?

        -  How does right ventricular function influence GEDV, GEF and CFI?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Cardiac Output, Preload values (GEDV)</measure>
    <time_frame>Day 1 only</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome measure is obtained during PiCCO measurement and left/right heart catherization, respectively (&quot;point-of-care&quot; measurement). There is no follow-up examination thereafter.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>LV-EF &gt; 50%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function [LV-EF &gt; 50%]</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiCCO Catheter (Pulsiocath 5F)</intervention_name>
    <description>Measuring of PiCCO derived values</description>
    <arm_group_label>LV-EF &gt; 50%</arm_group_label>
    <other_name>Pulsiocath 5F, Pulsion Medical Systems, Munich, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Coronary heart disease without impaired left ventricular function [LV-EF &gt; 50%]
             (n=10, control group)

          -  Coronary heart disease with impaired left ventricular function [LV-EF &lt; 50%] (n=10)

          -  Dilated cardiomyopathy (n=10),

          -  Aortic valve stenosis (n=10),

          -  Mitral valve regurgitation (n=10),

          -  Diastolic left ventricular dysfunction (n=10) and

          -  Right heart failure (n=10)

        Exclusion criteria:

          -  Patients with catecholamine dependent cardiogenic shock, severe respiratory distress
             because of pulmonary oedema, intubated patients, patients with atrial fibrillation,
             atrioventricular conduction abnormalities, and slow ventricular tachycardia will not
             be included.

          -  Moreover patients not being able to give informed consent are excluded. Even more,
             pregnant women are excluded from the study due to the radiation exposure in line with
             heart catheterization. A pregnancy test will be performed prior to participating with
             this study.

          -  The age does not represent an exclusion criterion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Maggiorini, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Medical Intensive Care Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <phone>+41 (0)44 255 11 11</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Franzen, MD</last_name>
      <phone>++411442551111</phone>
      <email>daniel.franzen@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marco Maggiorini, Prof.</last_name>
      <phone>++411442551111</phone>
      <email>marco.maggiorini@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>October 2, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
